Superworthbiote EPS BTMD
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- $0.10
- Latest quarter, Q2 FY26
- −$0.23
- −330% on a year earlier
- Fiscal year 2025
- $0.74
- +640% on the year before
biote's earnings per share was $0.10 over the twelve months to Jun 30, 2026, down 89% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.23, down 330% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.74 | +640% |
| FY2024 | $0.10 | n/a |
| FY2023 | −$0.17 | n/a |
| FY2022 | −$0.14 | −114% |
| FY2021 | $1.03 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.23 | −330% | $0.10 | |
| Q1 FY26 | $0.06 | −84% | $0.43 | |
| Q4 FY25 | $0.05 | −50% | $0.74 | |
| Q3 FY25 | $0.22 | −33% | $0.79 | |
| Q2 FY25 | $0.10 | n/a | $0.90 | |
| Q1 FY25 | $0.37 | n/a | $0.59 | |
| Q4 FY24 | $0.10 | −57% | $0.10 | |
| Q3 FY24 | $0.33 | +38% | $0.23 | |
| Q2 FY24 | −$0.21 | n/a | $0.14 | |
| Q1 FY24 | −$0.12 | n/a | $0.10 | |
| Q4 FY23 | $0.23 | +35% | −$0.17 | |
| Q3 FY23 | $0.24 | n/a | −$0.23 |
Against its peers
Companies in Basic Materials nearest biote's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BTMDbiote | $0.10 | −89% a year |
| BWENBroadwind | n/m | |
| FTLFFitlife Brands | $0.62 | −23% a year |
| SMIDSmith Midland | $1.45 | −36% a year |
| NAGENiagen Bioscience | $0.18 | −14% a year |
| SNDSmart Sand | $0.26 | +1200% a year |
| ALTOAlto Ingredients | $0.67 | |
| FRDFriedman Industries | $3.84 | +217% a year |
| IDRIdaho Strategic Resources | $1.42 | +115% a year |
| VFFVillage Farms International | $0.18 | +100% a year |
| Peer median | $0.65 |
Where biote ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on biote
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.